当前位置: X-MOL 学术Cell. Signal. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators
Cellular Signalling ( IF 4.8 ) Pub Date : 2020-12-03 , DOI: 10.1016/j.cellsig.2020.109871
Milad Ashrafizadeh 1 , Ali Zarrabi 2 , Kiavash Hushmandi 3 , Farid Hashemi 4 , Ebrahim Rahmani Moghadam 5 , Marzieh Owrang 5 , Fardin Hashemi 6 , Pooyan Makvandi 7 , Mohammad Ali Sheikh Beig Goharrizi 8 , Masoud Najafi 9 , Haroon Khan 10
Affiliation  

Cisplatin (CP) is a well-known chemotherapeutic agent with excellent clinical effects. The anti-tumor activity of CP has been demonstrated in different cancers such as breast, cervical, reproductive, lung, brain, and prostate cancers. However, resistance of cancer cells to CP chemotherapy has led to its failure in eradication of cancer cells, and subsequent death of patients with cancer. Fortunately, much effort has been put to identify molecular pathways and mechanisms involved in CP resistance/sensitivity. It seems that microRNAs (miRs) are promising candidates in mediating CP resistance/sensitivity, since they participate in different biological aspects of cells such as proliferation, migration, angiogenesis, and differentiation. In this review, we focus on miRs and their regulation in CP chemotherapy of lung cancer, as the most malignant tumor worldwide. Oncogenic miRs trigger CP resistance in lung cancer cells via targeting various pathways such as Wnt/β-catenin, Rab6, CASP2, PTEN, and Apaf-1. In contrast, onco-suppressor miRs inhibit oncogene pathways such as STAT3 to suppress CP resistance. These topics are discussed to determine the role of miRs in CP resistance/sensitivity. We also describe the upstream modulators of miRs such as lncRNAs, circRNAs, NF-κB, SOX2 and TRIM65 and their association with CP resistance/sensitivity in lung cancer cells. Finally, the effect of anti-tumor plant-derived natural compounds on miR expression during CP sensitivity of lung cancer cells is discussed.



中文翻译:

肺癌细胞及其对顺铂化疗的敏感性/抗性:微小RNA和上游介质的作用

顺铂(CP)是一种众所周知的化疗药物,具有良好的临床疗效。CP 的抗肿瘤活性已在不同的癌症中得到证实,例如乳腺癌、宫颈癌、生殖癌、肺癌、脑癌和前列腺癌。然而,癌细胞对CP化疗的耐药性导致其无法根除癌细胞,从而导致癌症患者死亡。幸运的是,已经付出了很多努力来确定参与 CP 抗性/敏感性的分子途径和机制。似乎 microRNA (miR) 是介导 CP 抗性/敏感性的有希望的候选者,因为它们参与细胞的不同生物学方面,如增殖、迁移、血管生成和分化。在这篇综述中,我们关注 miRs 及其在肺癌 CP 化疗中的调控,作为世界上最恶性的肿瘤。致癌 miRs 触发肺癌细胞中的 CP 抗性通过靶向多种途径,如 Wnt/β-catenin、Rab6、CASP2、PTEN 和 Apaf-1。相比之下,抑癌基因 miRs 抑制癌基因通路如 STAT3 以抑制 CP 抗性。讨论这些主题以确定 miR 在 CP 抗性/敏感性中的作用。我们还描述了 miR 的上游调节剂,如 lncRNA、circRNA、NF-κB、SOX2 和 TRIM65,以及它们与肺癌细胞中 CP 抗性/敏感性的关联。最后,讨论了抗肿瘤植物来源的天然化合物对肺癌细胞 CP 敏感性过程中 miR 表达的影响。

更新日期:2020-12-11
down
wechat
bug